Verandering in het management van gevorderd peniscarcinoom

Penile squamous cell carcinoma (PSCC) constitutes a rare yet clinically relevant malignancy, accounting for ∼1% of all new cancer cases in men worldwide; an estimated 37 700 new cases and 17 000 deaths attributable to PSCC occur annually.1 In Europe and in the United States, ∼7000 and 2000 men are diagnosed with PSCC each year, respectively, while an estimated 5000 cases occur in Latin America.1,2 Although most cases are diagnosed at a localized stage—when surgical resection, radiotherapy, and/or chemotherapy can achieve disease control rates of up to 70%2—the clinical course remains challenging.